She Wanted Implants. She Had Been on a Bone Medication for Nine Years.

Quick answer: Osteoporosis medication does not automatically rule out implants. The relevant question is which drug, at what dose, for how long, and why — oral tablets for osteoporosis carry a very different risk from high-dose intravenous treatment for cancer.

The call

She had been refused twice, both times in a single sentence, and both times without anyone asking which medication she was on.

Miriam, 71, from RBS Alef, wanted two implants to replace lower molars and stabilise a partial denture she disliked. She had been taking an oral bisphosphonate for osteoporosis for nine years.

The refusals may well have reached the right answer. They had not asked the right questions to know.

What we found

Two edentulous spaces in the lower right, healed and well healed, with adequate bone height above the nerve canal and reasonable width. Healthy gums, no periodontitis, no smoking, good hygiene, no diabetes.

The medication history, which is the assessment:

• Which drug. An oral bisphosphonate, weekly.
• What indication. Osteoporosis, not cancer. This is the largest single factor.
• Route. Oral, not intravenous.
• Duration. Nine years, which is long and matters.
• Any drug holiday. None.
• Other risk factors. No steroids, no chemotherapy, no head and neck radiotherapy, no smoking, no diabetes.

What the risk actually is. These drugs suppress bone turnover, which is how they work and also why they matter here. Medication-related osteonecrosis of the jaw is the concern: an area of exposed, non-healing bone following a procedure that involves the jawbone.

The risk figures differ by an order of magnitude depending on context. In patients taking oral bisphosphonates for osteoporosis, the reported incidence following dental procedures is very low — commonly cited in the range of hundredths of a per cent. In patients receiving high-dose intravenous bisphosphonates or denosumab for malignancy, it is very much higher.

Treating those two groups as one category is the error behind most blanket refusals.

Duration is the modifier that mattered here. Risk rises with cumulative exposure, and beyond about four to five years of oral therapy it is generally regarded as increased relative to shorter use. Nine years placed her above the low-risk baseline while remaining a long way below the oncology population.

Denosumab, a different drug used for the same indication, behaves differently — its effect is not cumulative in bone and reverses within months of stopping, which changes the planning entirely. She was not on it, but it is the reason "bone medication" is not a single category either.

What we did

Wrote to her doctor with three specific questions: confirmation of the drug, dose and duration; her current fracture risk; and whether a drug holiday was clinically acceptable.

The answer came back that her fracture risk was moderate, that she had had no fractures, and that a temporary interruption was acceptable in her case. That decision was the prescriber's, not ours.

A drug holiday of three months before surgery, at her doctor's direction. The evidence for this is not strong and it is commonly recommended in longer-duration oral cases; it was reasonable here because her physician judged the fracture risk acceptable.

Informed consent that was genuinely informed. Written, specific, with the actual risk described in numbers rather than adjectives, and the alternatives — a new partial denture, or a bridge — set out with their own trade-offs. She took it home for two weeks.

Surgery designed to minimise bone trauma: minimally invasive flapless placement guided by a surgical stent, copious irrigation, no bone reduction, primary closure, and a single dose of antibiotic prophylaxis.

Close follow-up: one week, three weeks, six weeks, three months, watching specifically for delayed healing or exposed bone.

The outcome

Both sites healed normally. The implants integrated and were restored at four months. Stable at three years.

She resumed her medication after healing, on her doctor's timetable.

The point is not that implants are safe on these medications. It is that the answer depends on drug, dose, duration and indication, and that "no" delivered without those questions is not an assessment.

What to do if this happens to you

1. Bring the exact drug name, dose and start date. "A bone tablet" is not enough information.
2. Say why you take it. Osteoporosis and cancer are entirely different risk categories.
3. Ask for the risk in numbers, not adjectives.
4. Expect your dentist to write to your doctor. Drug holidays are a medical decision.
5. Never stop the medication yourself. Fracture risk is real and immediate.
6. Ask about alternatives — a denture or bridge may be the better trade in some cases.

On bone medication and told no? Ramat Beit Shemesh Urgent Dental Care assesses properly before deciding. 055-985-8845 · WhatsApp https://wa.me/972559858845 · Harav Kook 28/1, Beit Shemesh

This is a composite clinical story. It reflects a presentation we see regularly in Beit Shemesh and Ramat Beit Shemesh; the name and details are illustrative and are not those of a real patient.